Innovation is of no worth if it doesn’t provide better outcomes for patients. Indeed, such advancements should hold as centre the amelioration of the overall patient experience. And that’s where digital developments and a Direct-To-Patient (DTP) approach come in.
As Frontiers Health 2024 approaches, taking place in Berlin 17th and 18th October, pharmaphorum sat down with one of its speakers, Scott Snyder, Chief Digital Officer at EVERSANA, to learn more about Snyder’s upcoming panels at the conference, and EVERSANA’s own DTP model.
Transforming the pharma commercial model with AI
In the first panel to be moderated by Snyder – who is also Senior Fellow in the Management Department at The Wharton School, as well as Digital Economy Platform Senior Fellow at the World Economic Forum – panellists will explore how generative AI (GenAI) is revolutionising, accelerating, and enhancing drug discovery, clinical trials, patient care, and commercialisation. With GenAI set to become a workforce partner for 90% of organisations globally in 2025, the question is, simply, whether organisations are ready.
Read more of this article from pharmaphorum
Connect With An Expert!
Author
Scott serves as EVERSANA’s Chief Digital Officer, driving digital transformation for employees, clients, and the patients we serve. He brings more than 30 years of experience in emerging technologies and digital transformation across both…